21 CFR Part 211 details the current good manufacture practice for finished pharmaceuticals. It covers requirements ... the component as labeled prior to release for use in drug product manufacturing.

These companies now have until December 31, 2025, to upgrade their facilities and meet the enhanced standards. The extension ...

To support compliance, the government revised Schedule M of the Drugs and Cosmetics Rules, 1945, in 2023, outlining phased ...

Gland Pharma Ltd. received the establishment inspection report from US FDA, confirming that the good manufacturing practices ...

India extended the deadline for small- and medium-sized pharmaceutical companies to comply with revised GMP compliance under ...

The new Schedule M will be implemented from 1 January, 2026, to help MSMEs adjust to updated manufacturing standards.

Telangana: Gland Pharma has received Establishment Inspection Report (EIR) from the United States Food and Drug ...

Small and medium-sized pharmaceutical companies are preparing to comply with the provisions of the revised Schedule M, which ...

Indian pharma with advancements in manufacturing, tech & healthcare access: Shardul Nautiyal, Mumbai Thursday, January 2, 2025, 08:00 Hrs [IST] The year 2 ...

Gland Pharma Ltd shares gained almost 3% on Thursday after the company announced receiving a Good Manufacturing Practice (GMP ...

Indore: With the mandatory enforcement of the revised Schedule M manufacturing standards implemented from January 1, 2025, the Food and Drug Administr.